- Conditions
- Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Leukemia, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Lymphoblastic Lymphoma
- Interventions
- Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide, Ofatumumab, Pegfilgrastim, Rituximab, Vincristine Sulfate Liposome
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 1,406
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Mediastinal Large B-Cell Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, Filgrastim, Lumbar Puncture, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Prednisolone, Prednisone, Radiation Therapy, Rituximab, Rituximab and Hyaluronidase Human, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 215
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 162 more
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm
- Interventions
- Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 84 more
- Conditions
- Lymphoma
- Interventions
- filgrastim, rituximab, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine
- Biological · Drug
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2019
- U.S. locations
- 104
- States / cities
- Palo Alto, California • Fort Collins, Colorado • Jacksonville, Florida + 69 more
- Conditions
- Nondependent Opioid Abuse, Episodic
- Interventions
- Placebo, MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Migraine
- Interventions
- Rimegepant, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 640 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 57
- States / cities
- Fort Smith, Arkansas • Hawthorne, California • La Mesa, California + 43 more
- Conditions
- Colo-rectal Cancer, Anesthesia
- Interventions
- IV Medications, placebo
- Drug · Other
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Familial Dysautonomia
- Interventions
- Albuterol-sulphate, Ipratropium-bromide, placebo
- Drug · Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Anemia
- Interventions
- Ferric Carboxymaltose (FCM), Ferrous Sulfate tablets
- Drug
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Norristown, Pennsylvania
- Conditions
- Thermal Burn
- Interventions
- thin Integra® (125 cm2)
- Device
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 18 Years to 125 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Healthy Volunteers
- Interventions
- itraconazole, rifampin, mitapivat sulfate
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Healthy Subjects
- Interventions
- Isavuconazonium sulfate IV, Isavuconazonium sulfate capsules
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Second Degree Burn
- Interventions
- Mepilex, Silvadene
- Device
- Lead sponsor
- Molnlycke Health Care AB
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Gainesville, Florida + 7 more
- Conditions
- Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone, Rituximab, Vincristine Sulfate, Zanubrutinib
- Drug · Biological
- Lead sponsor
- Yazeed Sawalha
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- Cleveland, Ohio • Columbus, Ohio • Charleston, South Carolina
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Diphenhydramine hydrochloride, Lymphocytes, Activated, Lamivudine, Zidovudine, Acetaminophen, Aldesleukin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2003
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy
- Interventions
- morphine sulfate sustained-release capsules, KADIAN
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Nasal Carriers of Staphylococcus Aureus
- Interventions
- Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Anemic, Critically Ill Patients
- Interventions
- Ferrous Sulfate, Placebo Oral Tablet
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Restless Legs Syndrome, Iron Deficiency Anemia
- Interventions
- Ferumoxytol intravenous, Ferrous sulfate
- Drug
- Lead sponsor
- Auerbach Hematology Oncology Associates P C
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Lymphoma
- Interventions
- Duvelisib, Rituximab, R-CHOP, Prednisone
- Drug
- Lead sponsor
- SecuraBio
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- STAHIST NDC #58407-536-01
- Drug
- Lead sponsor
- Magna Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Lymphoma
- Interventions
- rituximab, bortezomib, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 147
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 95 more
- Conditions
- Hodgkin Lymphoma
- Interventions
- Brentuximab vedotin, Doxorubicin, Vinblastine, Dacarbazine, Pembrolizumab, Gemcitabine, Vinorelbine, FDG-PET/CT scan
- Drug · Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- Pain
- Interventions
- Codeine Sulfate
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Austin, Texas